Abstract: A percutaneous absorption accelerator and a percutaneous absorbent preparation containing the same and, more particularly, a percutaneous absorption accelerator containing either derivatives of specific glycerols or polyglycerols and alcohols as effective components and a percutaneous absorbent preparation containing the percutaneous absorption accelerators and pharmaceutically effective components.

Abstract: An arrangement is provided for the application of an oral pharmaceutical to the mucosa of the oral or nasal cavity, for sustained release there of the drug. The arrangement of the invention comprises a body which has a size and shape suitable for insertion into and retention in the oral or nasal cavity, the body being formed of granules of a higher aliphatic alcohol and a hydrated water soluble hydroxyalkyl cellulose having the drug distributed therethrough. This body is coated with a cellulose derivative which is adherent to the mucosa. As a consequence, upon insertion into the oral or nasal cavity, the body adheres to the mucosa and the drug is there slowly released and absorbed into the body. The arrangement is preferably in the form of a buccal tablet, particularly a kidney shaped buccal tablet. Any drug suitable for oral administration can be used, morphine being preferred. The cellulose derivative which is preferred is hydroxypropyl cellulose.

Abstract: A controlled release composition comprising a prostaglandin and a polymeric carrier therefor comprising residues having a ratio of number average molecular weight to functionality greater than 1,000 which comprise polyethylene oxide and are cross-linked through urethane groups.

Abstract: Medicinal compositions containing a water soluble absorption promoter having chelating activity, preferably in the presence of a salt at a concentration exhibiting higher osmotic pressure than isotonic sodium chloride solution, to promote absorption of the medicine through a gastrointestinal organ such as colon or rectum, and through the vagina.

Abstract: A controlled release composition comprising an active substance other than a prostaglandin and a polymeric carrier therefor comprising residues having a ratio of number average molecular weight to functionality greater than 1000 which comprises polyethylene oxide and are cross-linked through urethane groups.

Abstract: A preparation containing an absorption promoter selected from N-acyl amino acid derivatives or N-acyl peptide derivatives represented by the formula: R-CO-A (R is an aliphatic hydrocarbon group, an aromatic hydrocarbon group or an aryl-substituted lower hydrocarbon group which may optionally be substituted, and A is an amino acid residue or a peptide residue), preferably in the presence of a salt at a concentation exhibiting higher osmotic pressure than isotonic sodium chloride solution, and a medicine is found to promote absorption of the medicine through a gastrointestinal organ such as the colon and rectum, and through the vagina.

Abstract: An enteral non-adjuvenated monobacterial vaccine comprising killed bacteria gives a better protection against acute episodes of infection in patients with long term chronic lung disease than a conventional adjuvenated polybacterial vaccine. The bacteria are usually Haemophilus influenza, Streptococcus pneumoniae, Pseudomonas aeruginosa or Staphylococcus aureus.

Abstract: A composition of matter comprising a drug, a neutral hydrogel and an ionic hydrogel. The composition can be administered from a delivery system to a biological receptor over time.

Abstract: An osmotic dosage system is disclosed for delivering the therapeutically beneficial drug doxazosin to an environment of use over time.

Abstract: A diuretically active combination comprising furosemide and triamterene in a ratio of 1:1 to 1:2, in which furosemide is in the form of controlled release so as to facilitate solubilization of the furosemide in triamterene micelles to stabilize the combination as mixed micelles of low polydispersity yielding dissolution rates in in vitro tests of furosemide of not more than about 1.5% after about one hour at pH 1.5 to 3.5 and a slow release of not more than about 4.5% at pH 5.5 concurrent with a release of triamterene of about 60-70% and 80%, respectively, and with a release of not more than 85% furosemide after eight hours at pH 7.5 in salt solutions of adjusted pH.

Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5.dbd.-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.

Abstract: A pharmaceutical composition for suppository which comprises buprenorphine or its pharmaceutically acceptable acid addition salt as the active ingredient and a mixed base composed of 70 to 95 wt. % of polyethylene glycol with average molecular weight of 200 to 20,000 and 30 to 5 wt. % of propylene glycol.

Abstract: The invention relates to a controlled release dosage form comprising three actives: acetaminophen, pseudoephedrine and dexbrompheniramine.

Abstract: This invention is directed to a delivery system and a method useful for preventing pregnancy in female mammals by administering an LHRH composition. The method comprises administering during the entire follicular phase of the menstrual cycle, beginning at the time of menses, an LHRH composition and sufficient levels of an estrogenic steroid to counteract the possibility of side effects which may develop during prolonged therepy with LHRH. Following the follicular phase, at the beginning of the luteal phase, and for the entire course of the luteal phase, the LHRH/estrogenic steroid combination administered during the follicular phase, in combination with a physiological amount of progestational steroid, is administered.The delivery system comprises means for administering the LHRH composition, estrogenic steroid and progestational steroid.

Abstract: Controlled release solid dosage forms comprising less than about one-third of the total dosage form weight of hydroxypropylmethylcellulose USP 2910 are disclosed.

Abstract: A furazolidone dosage unit form comprises the drug furazolidone, a sustained release matrix, and an enteric coating.